Age (years, mean) | 35 (10 studies, n = 240) |
Male sex (%) | 39.6 (15 studies, n = 315) |
CD4 count (cells/microL, median, IQR) | 48 [31.5–129.0] (16 studies, n = 353) |
Cotrimoxazole prophylaxis (%, 95 % CI) | 5.9 [3.3–9.5] (11 studies, n = 255) |
ART (%, 95 % CI) | 0.4 [0.01–2.6] (11 studies, n = 215) |
Co-existent opportunistic disease (%, 95 % CI) | |
- Overall | 29.3 [25.4–33.6] (26 studies, n = 474) |
- Tuberculosis | 14.8 [11.8–18.5] (25 studies, n = 431) |
- Bacterial pneumonia | 8.7 [0.6–11.8] (22 studies, n = 445) |
- Pulmonary cryptococcosis | 1.4 [0.4–3.6] (17 studies, n = 283) |
- Pulmonary Kaposi sarcoma | 4.1 [2.4–6.6] (21 studies, n = 410) |
- Pulmonary CMV | 3.9 [1.4–8.2] (11 studies, n = 155) |
- Pulmonary MAC | 0.8 [0.1–2.8] (19 studies, n = 254) |
Case fatality rate (%, 95 % CI) | 18.8 % [11.0–26.5] (12 studies, n = 334) |